title: 200 mg/m(2) melphalan--the gold standard for multiple myeloma.
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
mesh_terms: D000367:Age Factors; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan
references.citation: Bone Marrow Transplant. 2007 Jun;39(12):759-66
references.pmid: 17438588
references.citation: Blood. 2002 Feb 1;99(3):731-5
references.pmid: 11806971
references.citation: Blood. 2010 Mar 11;115(10):1873-9
references.pmid: 19965659
references.citation: Biol Blood Marrow Transplant. 2004 Jul;10(7):473-83
references.pmid: 15205668
references.citation: J Clin Oncol. 2010 May 20;28(15):2612-24
references.pmid: 20385994
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1319-28
references.pmid: 11870175
references.citation: Blood. 2006 Jan 1;107(1):397-403
references.pmid: 16144800
references.citation: J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S21-7
references.pmid: 20141671